Search research articles
Contact Us
Filters
Showing results (81-90 of 210) with videos related to
Page
of 21
Sort By:
Oncotargets and Therapy
|
December 26, 2013
Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
Srdan Verstovsek, Jason Gotlib, Vikas Gupta, et al.
Leukemia Research
|
June 19, 2022
Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database
Noa Rippel, Douglas Tremblay, Nicole Zubizarreta, et al.
Leukemia Research
|
June 3, 2021
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database
Douglas Tremblay, Lukas Ronner, Nikolai Podoltsev, et al.
The New England Journal of Medicine
|
August 13, 2004
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Catriona H M Jamieson, Laurie E Ailles, Scott J Dylla, et al.
Journal of Hematology & Oncology
|
October 1, 2017
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
Srdan Verstovsek, Jason Gotlib, Ruben A Mesa, et al.
The Journal of Allergy and Clinical Immunology
|
April 14, 2022
Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?
Peter Valent, Cem Akin, Karin Hartmann, et al.
Blood
|
July 11, 2013
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Ayalew Tefferi, Francisco Cervantes, Ruben Mesa, et al.
Cancer Cell
|
April 9, 2008
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors
Ifat Geron, Annelie E Abrahamsson, Charlene F Barroga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 2, 2022
Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis
Johannes Lübke, Juliana Schwaab, Nicole Naumann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2017
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis
Ruben A Mesa, Jean-Jacques Kiladjian, John V Catalano, et al.
Page
of 21
Search research articles
Search
Showing results (81-90 of 210) with videos related to
Sort By:
Page
of 21
Oncotargets and Therapy
|
December 26, 2013
Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
Srdan Verstovsek, Jason Gotlib, Vikas Gupta, et al.
Leukemia Research
|
June 19, 2022
Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database
Noa Rippel, Douglas Tremblay, Nicole Zubizarreta, et al.
Leukemia Research
|
June 3, 2021
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database
Douglas Tremblay, Lukas Ronner, Nikolai Podoltsev, et al.
The New England Journal of Medicine
|
August 13, 2004
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Catriona H M Jamieson, Laurie E Ailles, Scott J Dylla, et al.
Journal of Hematology & Oncology
|
October 1, 2017
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
Srdan Verstovsek, Jason Gotlib, Ruben A Mesa, et al.
The Journal of Allergy and Clinical Immunology
|
April 14, 2022
Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?
Peter Valent, Cem Akin, Karin Hartmann, et al.
Blood
|
July 11, 2013
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Ayalew Tefferi, Francisco Cervantes, Ruben Mesa, et al.
Cancer Cell
|
April 9, 2008
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors
Ifat Geron, Annelie E Abrahamsson, Charlene F Barroga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 2, 2022
Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis
Johannes Lübke, Juliana Schwaab, Nicole Naumann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2017
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis
Ruben A Mesa, Jean-Jacques Kiladjian, John V Catalano, et al.
Page
of 21